This review examines the development pipeline for new TB vaccines and the challenges involved in moving vaccine candidates from preclinical research through clinical trials and eventual introduction. It discusses different vaccine platforms and candidates, clinical trial design, immune correlates of protection, regulatory requirements, funding, and the need for coordinated development programmes. It also highlights key barriers that could delay the availability of an effective TB vaccine and discusses the priorities for accelerating vaccine development